Table 1.
Antibody Combinations for Characterization of B Cells*
| FITC | PE | PerCP/Cy5.5 | PC7 | APC | AH7 | V500 | V450 |
|---|---|---|---|---|---|---|---|
| CD103 | CD25 | CD20 | — | CD11c | — | — | — |
| — | CD123 | CD20 | — | CD-X | — | — | — |
| — | CD123 | CD19 | — | CD-X | — | — | — |
| κ | λ | CD19 | — | CD-X | CD-X | — | — |
| κ | CD22 | CD20 | — | CD-X | CD-X | — | — |
| λ | CD22 | CD20 | — | CD-X | CD-X | — | — |
| κ | CD22 | CD5 | CD19 | CD10 | CD20 | CD45 | CD11c |
| λ | CD22 | CD5 | CD19 | CD10 | CD20 | CD45 | CD11c |
| CD103 | CD25 | CD123 | CD19 | CD23 | CD20 | CD45 | CD11c |
AH7, allophycocyanin/cyanin tandem conjugate; APC, allophycocyanin; Cy, cyanine; FITC, fluorescein isothiocyanate; PC7, phycoerythrin/cyanin dye 7 tandem conjúgate; PE,phycoerythrin; PerCP, peridinin chlorophyll protein.
*
For hairy cell leukemia and hairy cell leukemia-variant specimens, X indicates CD11c; for mantle cell lymphoma and chronic lymphocytic leukemia, X indicates CD5; forfollicular lymphoma, X indicates CD10; for splenic marginal zone lymphoma cases, X indicates CD5, CD10, or CD11c, depending on the submitted patient history. The panelof antibodies for initial screening also included CD2, CD3, CD4, CD5, CD7, CD8, CD14, CD16, CD56, CD57, T-cell receptor (TCR)ap, and TCRyó.